Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 27:2022:7776092.
doi: 10.1155/2022/7776092. eCollection 2022.

Budesonide-Loaded Hyaluronic Acid Nanoparticles for Targeted Delivery to the Inflamed Intestinal Mucosa in a Rodent Model of Colitis

Seyed Yaser Vafaei  1   2 , Amir Hossein Abdolghaffari  3   4 , Reza Mahjub  2 , Seyyed Majid Eslami  5 , Motahareh Esmaeili  6 , Mohammad Abdollahi  5 , Fatemeh Atyabi  1   6 , Rassoul Dinarvand  1   6
Affiliations

Budesonide-Loaded Hyaluronic Acid Nanoparticles for Targeted Delivery to the Inflamed Intestinal Mucosa in a Rodent Model of Colitis

Seyed Yaser Vafaei et al. Biomed Res Int. .

Abstract

The aim of the present study was to investigate the therapeutic potential of budesonide- (BDS-) loaded hyaluronic acid nanoparticles (HANPs) for treatment of inflammatory bowel disease (IBD) using an acute model of colitis in rats. The therapeutic efficacy of BDS-loaded HANPs in comparison with an aqueous suspension of the drug with the same dose (30 μg/kg) was investigated 48 h following induction of colitis by intrarectal administration of acetic acid 4% in rats. Microscopic and histopathologic examinations were conducted in inflamed colonic tissue. Tissue concentration of tumor necrosis factor (TNF)-α was assessed by ELISA assay kit, while the activity of myeloperoxidase (MPO) was measured spectrophotometrically. Results from in vivo evaluations demonstrated that administrations of BDS-HANPs ameliorated the general endoscopic appearance, quite close to the healthy animals with no signs of inflammation and reduced the cellular infiltration, as well as the TNF-α level, and the MPO activity. It was found that delivery by BDS-loaded HANPSs alleviated the induced colitis significantly better than the same dose of the free drug. These data further suggest the potential of HANPs as a targeted drug delivery system to the inflamed colon mucosa.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
(a) The size distribution (a) and morphologies (b) SEM image. (c) TEM image (bar = 500 nm) of the BDS-loaded HA NPs (b).
Figure 2
Figure 2
Photographs of the colon of rat after the induction of colitis with acetic acid sacrificed on day 7: (a) (sham or normal group; group I), (b) (untreated acetic acid group; group V), (c) (blank nanoparticles treated group; group II), (d) (budesonide suspension treated group; group III), (e) (budesonide-loaded HA nanoparticle treated group; group IV).
Figure 3
Figure 3
Macroscopic scoring of colonic injuries in different animal groups. aSignificantly different from sham (group I) (p < 0.05). bSignificantly different from control (group V) (p < 0.05). cSignificantly different from the blank-treated group (group II) (p < 0.05),d Significantly different from the BDS Susp-treated group (group III) (p < 0.05).
Figure 4
Figure 4
Microscopic images of colonic tissues obtained from (a) sham or normal group (group I); (b) control group (group V); (c) animal group which received blank nanoparticles (group II); (d) animal group which received free BDS (group III); (e) animal group which received BDS nanoparticles (group IV).
Figure 5
Figure 5
Microscopic scoring of colonic injuries in different animal groups. aSignificantly different from sham (group I) (p < 0.05). bSignificantly different from control (group V) (p < 0.05). cSignificantly different from the blank-treated group (group II) (p < 0.05). dSignificantly different from the BDS Susp-treated group (group III) (p < 0.05).
Figure 6
Figure 6
MPO activity in colonic samples of different animal groups. (a) Significantly different from sham (group I) (p < 0.05). (b) Significantly different from control (group V) (p < 0.05). (c) Significantly different from the blank-treated group (group II) (p < 0.05). (d) Significantly different from the BDS Susp-treated group (group III) (p < 0.05).
Figure 7
Figure 7
Level of TNF-α in colonic sample of different animal groups. (a) Significantly different from sham (group I) (p < 0.05). (b) Significantly different from control (group V) (p < 0.05). (c) Significantly different from the blank-treated group (group II) (p < 0.05). (d) Significantly different from the BDS Susp-treated group (group III) (p < 0.05).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Baumgart D. C., Sandborn W. J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. The Lancet . 2007;369(9573):1641–1657. doi: 10.1016/S0140-6736(07)60751-X. - DOI - PubMed
    1. Khor B., Gardet A., Xavier R. J. Genetics and pathogenesis of inflammatory bowel disease. Nature . 2011;474(7351):307–317. doi: 10.1038/nature10209. - DOI - PMC - PubMed
    1. Sartor R. B. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nature Clinical Practice Gastroenterology & Hepatology . 2006;3(7):390–407. doi: 10.1038/ncpgasthep0528. - DOI - PubMed
    1. Cai Z., Wang S., Li J. Treatment of inflammatory bowel disease: a comprehensive review. Frontiers in Medicine . 2021;8, article 765474 doi: 10.3389/fmed.2021.765474. - DOI - PMC - PubMed
    1. Curkovic I., Egbring M., Kullak-Ublick G. A. Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates. Digestive Diseases . 2013;31(3-4):368–373. doi: 10.1159/000354699. - DOI - PubMed